| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 | SCHEDULE 13D/A |
| 12 Nov 2026 |
Form 4: Rtw INVESTMENTS, Lp, 10% owner and 1 other
Bought 1,200,000 shares ($6M) |
| 10 Nov 2026 | 10-Q |
| 09 Nov 2026 |
Form 4: Fain Eric S, Director
Bought 20,000 shares ($100K) |
| 09 Nov 2026 |
Form 4: Pacitti David, Director
Bought 20,000 shares ($100K) |
| 09 Nov 2026 |
Form 4: Hochman David P, Director
Bought 5,000 shares ($25K) |
| 09 Nov 2026 |
Form 4: Taylor Andrew Lawrence, Chief Financial Officer
Bought 1,000 shares ($5K) |
| 09 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Orchestra BioMed Holdings, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 15,000,000 shares (the “Firm Shares”) of Common Stock, ... |
| 06 Nov 2026 | 424B5 |
| 05 Nov 2026 | 424B5 |
| 03 Nov 2026 |
Form 4: Sherman Darren, Director
Sold 15,000 shares ($86.1K) |
| 02 Nov 2026 | 144 |
| 02 Oct 2026 |
Form 4: Sherman Darren, Director
Sold 15,000 shares ($95.4K) |
| 01 Oct 2026 | 144 |
| 01 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
330 patients randomized as of September 30, 2026, surpassing full trial enrollment target |
| 11 Sep 2026 |
Form 4: Hochman David P, Director
Gave up 3,283 shares to cover exercise price or tax ($19.1K) · Gave up 3,283 shares to cover exercise price or tax ($19.1K) |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure
Accelerating high - impact technologies to patients through risk - reward sharing partnerships Corporate Overview | September 2026 Nasdaq : OBIO |
| 08 Sep 2026 |
Form 4: Hochman David P, Director
Bought 10,000 shares ($47.9K) |
| 02 Sep 2026 |
Form 4: Sherman Darren, Director
Sold 15,000 shares ($74.1K) |
Loading...